Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Atorvastatin on Prostate Cancer Progression After Initiation of Androgen Deprivation Therapy - Lipid Metabolism as a Novel Biomarker to Predict Prostate Cancer Progression

NCT04026230 is registered in ClinicalTrials.gov with Tampere University Hospital as lead sponsor.

NCT NCT04026230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04026230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Atorvastatin on Prostate Cancer Progression After Initiation of Androgen Deprivation Therapy - Lipid Metabolism as a Novel Biomarker to Predict Prostate Cancer Progression
Lead sponsor
Tampere University Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
August 15, 2019
Completion date
December 31, 2025
Enrollment
400 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, recurrent prostate cancer